ADDITIVITY OF NEBIVOLOL/VALSARTAN SINGLE-PILL COMBINATIONS VERSUS OTHER APPROVED SINGLE-PILL COMBINATIONS FOR HYPERTENSION

Jack Ishak,Michael Rael,Henry Punzi,Alan H. Gradman,Lynn M. Anderson, Sanjida Ali,William G. Ferguson,Joel M. Neutel

Journal of the American College of Cardiology（2017）

引用 6|浏览17

暂无评分

摘要

Background: The single-pill combination (SPC) comprising nebivolol (5 mg), a vasodilatory β1-selective antagonist/ β3 agonist, and valsartan (80 mg), an angiotensin receptor blocker, is the only FDA-approved β-blocker/renin-angiotensin-aldosterone system (RAAS) inhibitor SPC for hypertension.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要